Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lidocaine + sevoflurane
- Development stage
- Unknown
- Lead developer
- Maruishi Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous, Inhalation
01
Overview
A combination of the local anesthetic lidocaine and the inhalational anesthetic sevoflurane. Intravenous lidocaine is used as an adjunct to sevoflurane anesthesia to reduce sevoflurane requirements, suppress airway reflexes, improve hemodynamic stability, and enhance recovery profiles. Lidocaine decreases the minimum alveolar concentration (MAC) of sevoflurane by approximately 15-21%, allowing for lower sevoflurane dosing while maintaining adequate anesthesia depth.
02
Targets
NaV (Voltage-gated sodium channels)Glycine receptorNMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on lidocaine + sevoflurane.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lidocaine + sevoflurane.